TOKYO (Reuters) – Fujifilm Holdings Corp said on Wednesday its Avigan drug met the primary endpoint in a Phase 3 clinical trial for COVID-19 patients in Japan.
Japan had urged Fujifilm to triple national stockpiles of Avigan, approved in 2014 as an emergency flu treatment, and pledged to donate it to other countries.
(Reporting by)
